Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott T Tagawa

Showing results (1-10 of 208) with videos related to

Pageof 21
Sort By:
The Journal of Urology|July 21, 2009
Editorial commentScott T Tagawa
Clinical Advances in Hematology & Oncology : H&O|February 17, 2021
PSMA-targeted therapy in prostate cancerScott T Tagawa
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2014
Neuroendocrine prostate cancer after hormonal therapy: knowing is half the battleScott T Tagawa
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2021
Reply to T. Powles et alScott T Tagawa, Petros Grivas
Asian Journal of Andrology|August 23, 2011
Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancerScott T Tagawa, Himisha Beltran
The Journal of Urology|November 16, 2010
Editorial commentNaveed H Akhtar, Scott T Tagawa
The Lancet. Oncology|January 9, 2013
2-weekly versus 3-weekly docetaxel for prostate cancerDavid M Nanus, Scott T Tagawa
Lancet (London, England)|December 13, 2016
Immune-checkpoint blockade in cisplatin-ineligible patients with urothelial cancerBishoy M Faltas, Scott T Tagawa
Urologic Oncology|July 5, 2021
A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of penile cancerTimothy A Masterson, Scott T Tagawa
Urologic Oncology|April 15, 2021
A 25-year review of advances in testicular cancer: Perspectives on evaluation, treatment, and future directions/challengesTimothy A Masterson, Scott T Tagawa
Pageof 21

Showing results (1-10 of 208) with videos related to

Sort By:
Pageof 21
The Journal of Urology|July 21, 2009
Editorial commentScott T Tagawa
Clinical Advances in Hematology & Oncology : H&O|February 17, 2021
PSMA-targeted therapy in prostate cancerScott T Tagawa
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2014
Neuroendocrine prostate cancer after hormonal therapy: knowing is half the battleScott T Tagawa
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2021
Reply to T. Powles et alScott T Tagawa, Petros Grivas
Asian Journal of Andrology|August 23, 2011
Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancerScott T Tagawa, Himisha Beltran
The Journal of Urology|November 16, 2010
Editorial commentNaveed H Akhtar, Scott T Tagawa
The Lancet. Oncology|January 9, 2013
2-weekly versus 3-weekly docetaxel for prostate cancerDavid M Nanus, Scott T Tagawa
Lancet (London, England)|December 13, 2016
Immune-checkpoint blockade in cisplatin-ineligible patients with urothelial cancerBishoy M Faltas, Scott T Tagawa
Urologic Oncology|July 5, 2021
A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of penile cancerTimothy A Masterson, Scott T Tagawa
Urologic Oncology|April 15, 2021
A 25-year review of advances in testicular cancer: Perspectives on evaluation, treatment, and future directions/challengesTimothy A Masterson, Scott T Tagawa
Pageof 21